Unlike GLP-1 receptor agonists, which enhance insulin secretion and sensitivity, SGLT2 inhibitors complement diabetes management by reducing glucose reabsorption in the kidneys, promoting glycosuria, and subsequently lowering blood glucose levels. Here, INS is linked to diabetes mellitus.